PMID- 32938504
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20231112
IS  - 2049-9957 (Electronic)
IS  - 2095-5162 (Print)
IS  - 2049-9957 (Linking)
VI  - 9
IP  - 1
DP  - 2020 Sep 16
TI  - Reverse vaccinology assisted designing of multiepitope-based subunit vaccine 
      against SARS-CoV-2.
PG  - 132
LID - 10.1186/s40249-020-00752-w [doi]
LID - 132
AB  - BACKGROUND: Coronavirus disease 2019 (COVID-19) linked with severe acute 
      respiratory syndrome coronavirus 2 (SARS-CoV-2) cause severe illness and 
      life-threatening pneumonia in humans. The current COVID-19 pandemic demands an 
      effective vaccine to acquire protection against the infection. Therefore, the 
      present study was aimed to design a multiepitope-based subunit vaccine (MESV) 
      against COVID-19. METHODS: Structural proteins (Surface glycoprotein, Envelope 
      protein, and Membrane glycoprotein) of SARS-CoV-2 are responsible for its prime 
      functions. Sequences of proteins were downloaded from GenBank and several 
      immunoinformatics coupled with computational approaches were employed to forecast 
      B- and T- cell epitopes from the SARS-CoV-2 highly antigenic structural proteins 
      to design an effective MESV. RESULTS: Predicted epitopes suggested high 
      antigenicity, conserveness, substantial interactions with the human leukocyte 
      antigen (HLA) binding alleles, and collective global population coverage of 
      88.40%. Taken together, 276 amino acids long MESV was designed by connecting 3 
      cytotoxic T lymphocytes (CTL), 6 helper T lymphocyte (HTL) and 4 B-cell epitopes 
      with suitable adjuvant and linkers. The MESV construct was non-allergenic, 
      stable, and highly antigenic. Molecular docking showed a stable and high binding 
      affinity of MESV with human pathogenic toll-like receptors-3 (TLR3). Furthermore, 
      in silico immune simulation revealed significant immunogenic response of MESV. 
      Finally, MEV codons were optimized for its in silico cloning into the Escherichia 
      coli K-12 system, to ensure its increased expression. CONCLUSION: The MESV 
      developed in this study is capable of generating immune response against 
      COVID-19. Therefore, if designed MESV further investigated experimentally, it 
      would be an effective vaccine candidate against SARS-CoV-2 to control and prevent 
      COVID-19.
FAU - Tahir Ul Qamar, Muhammad
AU  - Tahir Ul Qamar M
AD  - College of Life Science and Technology, Guangxi University, Nanning, P. R. China.
FAU - Shahid, Farah
AU  - Shahid F
AD  - Department of Bioinformatics and Biotechnology, Government College University 
      Faisalabad (GCUF), Faisalabad, Pakistan.
FAU - Aslam, Sadia
AU  - Aslam S
AD  - Jinnah Hospital, Lahore, Pakistan.
FAU - Ashfaq, Usman Ali
AU  - Ashfaq UA
AD  - Department of Bioinformatics and Biotechnology, Government College University 
      Faisalabad (GCUF), Faisalabad, Pakistan. usmancemb@gmail.com.
FAU - Aslam, Sidra
AU  - Aslam S
AD  - Department of Bioinformatics and Biotechnology, Government College University 
      Faisalabad (GCUF), Faisalabad, Pakistan.
FAU - Fatima, Israr
AU  - Fatima I
AD  - Department of Bioinformatics and Biotechnology, Government College University 
      Faisalabad (GCUF), Faisalabad, Pakistan.
FAU - Fareed, Muhammad Mazhar
AU  - Fareed MM
AD  - Department of Bioinformatics and Biotechnology, Government College University 
      Faisalabad (GCUF), Faisalabad, Pakistan.
FAU - Zohaib, Ali
AU  - Zohaib A
AD  - Department of Healthcare Biotechnology, Atta-ur-Rahman School of Applied 
      Biosciences (ASAB), National University of Sciences and Technology (NUST), 
      Islamabad, Pakistan.
FAU - Chen, Ling-Ling
AU  - Chen LL
AD  - College of Life Science and Technology, Guangxi University, Nanning, P. R. China. 
      llchen@mail.hzau.edu.cn.
LA  - eng
GR  - Starting Research Grant for High-level Talents/Guangxi University/
GR  - Postdoctoral Project/Guangxi University/
PT  - Journal Article
DEP - 20200916
PL  - England
TA  - Infect Dis Poverty
JT  - Infectious diseases of poverty
JID - 101606645
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Epitopes, B-Lymphocyte)
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (Spike Glycoprotein, Coronavirus)
RN  - 0 (TLR3 protein, human)
RN  - 0 (Toll-Like Receptor 3)
RN  - 0 (Vaccines, Subunit)
RN  - 0 (Viral Matrix Proteins)
RN  - 0 (Viral Vaccines)
RN  - 0 (membrane protein, SARS-CoV-2)
RN  - 0 (spike protein, SARS-CoV-2)
SB  - IM
MH  - Betacoronavirus/*immunology
MH  - COVID-19
MH  - COVID-19 Vaccines
MH  - Coronavirus Infections/genetics/immunology/*prevention & control
MH  - Epitopes, B-Lymphocyte/chemistry/genetics/*immunology
MH  - Epitopes, T-Lymphocyte/chemistry/genetics/*immunology
MH  - Humans
MH  - Immunogenicity, Vaccine/immunology
MH  - Molecular Docking Simulation
MH  - Pandemics/*prevention & control
MH  - Pneumonia, Viral/immunology/*prevention & control
MH  - SARS-CoV-2
MH  - Sequence Analysis, Protein
MH  - Spike Glycoprotein, Coronavirus/chemistry/genetics/immunology
MH  - Toll-Like Receptor 3/chemistry/genetics/immunology
MH  - Vaccines, Subunit/chemistry/genetics/immunology
MH  - Vaccinology/methods
MH  - Viral Matrix Proteins/chemistry/genetics/immunology
MH  - Viral Vaccines/chemistry/genetics/*immunology
PMC - PMC7492789
OTO - NOTNLM
OT  - COVID-19
OT  - Epitope
OT  - Immunoinformatics
OT  - Multiepitope-based subunit vaccine
OT  - SARS-CoV-2
OT  - Structural protein
OT  - Vaccine
COIS- All authors have no competing interests.
EDAT- 2020/09/18 06:00
MHDA- 2020/09/25 06:00
PMCR- 2020/09/16
CRDT- 2020/09/17 05:32
PHST- 2020/04/29 00:00 [received]
PHST- 2020/09/08 00:00 [accepted]
PHST- 2020/09/17 05:32 [entrez]
PHST- 2020/09/18 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
PHST- 2020/09/16 00:00 [pmc-release]
AID - 10.1186/s40249-020-00752-w [pii]
AID - 752 [pii]
AID - 10.1186/s40249-020-00752-w [doi]
PST - epublish
SO  - Infect Dis Poverty. 2020 Sep 16;9(1):132. doi: 10.1186/s40249-020-00752-w.